NASDAQ:INM InMed Pharmaceuticals (INM) Stock Price, News & Analysis $0.29 +0.01 (+3.59%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.27▼$0.2950-Day Range$0.22▼$0.3552-Week Range$0.21▼$2.08Volume3.26 million shsAverage Volume1.40 million shsMarket Capitalization$2.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get InMed Pharmaceuticals alerts: Email Address Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About InMed Pharmaceuticals Stock (NASDAQ:INM)InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More INM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INM Stock News HeadlinesJuly 27 at 5:38 AM | americanbankingnews.comInMed Pharmaceuticals Inc. (NASDAQ:INM) Short Interest UpdateJuly 25 at 12:19 PM | theglobeandmail.comInMed’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular DegenerationJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.April 17, 2024 | theglobeandmail.comInMed (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMDMarch 23, 2024 | theglobeandmail.comInMed Pharmaceuticals (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day ExtensionFebruary 10, 2024 | markets.businessinsider.comInMed Pharmaceuticals Welcomes New CFO Neeta JagpalFebruary 10, 2024 | msn.comInMed Pharmaceuticals Announces New CFO AppointmentFebruary 9, 2024 | finance.yahoo.comInMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial OfficerJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.January 25, 2024 | benzinga.comInMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet NeedJanuary 18, 2024 | finance.yahoo.comInMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ETDecember 20, 2023 | finanznachrichten.deInMed Pharmaceuticals: InMed Announces Results of 2023 Annual General MeetingDecember 19, 2023 | finance.yahoo.comInMed Announces Results of 2023 Annual General MeetingNovember 14, 2023 | finance.yahoo.comInMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business UpdateNovember 8, 2023 | msn.comInMed Pharmaceuticals files to sell 12.57M shares for holdersNovember 8, 2023 | morningstar.comInMed Pharmaceuticals Inc INMNovember 2, 2023 | finance.yahoo.comInMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023October 27, 2023 | finance.yahoo.comInMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq RulesSee More Headlines Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)10/04/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INM CUSIPN/A CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,950,000.00 Net Margins-108.02% Pretax Margin-108.00% Return on Equity-53.42% Return on Assets-45.36% Debt Debt-to-Equity Ratio0.07 Current Ratio6.58 Quick Ratio5.80 Sales & Book Value Annual Sales$4.14 million Price / Sales0.62 Cash FlowN/A Price / Cash FlowN/A Book Value$3.63 per share Price / Book0.08Miscellaneous Outstanding Shares8,920,000Free Float8,795,000Market Cap$2.57 million OptionableNot Optionable Beta0.29 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Eric A. Adams B.S. Chem. (Age 61)M.I.B., President, CEO & Director Comp: $347.82kMr. Michael Woudenberg P.Eng. (Age 55)Chief Operating Officer Comp: $287.54kMs. Alexandra Diane-Janet Mancini M.Sc. (Age 71)Senior Vice President of Clinical & Regulatory Affairs Comp: $279.39kDr. Sazzad Hossain M.Sc. (Age 66)Ph.D., Co-Founder Comp: $135.99kMs. N. Netta Jagpal (Age 51)CFO & Corporate Secretary Ms. Sarah Li CPACGA, VP of Accounting & ControllerColin ClancySenior Director of Investor RelationsMr. Jerry P. GriffinVice President of Sales & MarketingDr. Eric Chih-Hsien Hsu (Age 54)Senior Vice President of Preclinical Research & Development Comp: $253.46kDr. Shane A. Johnson Ph.D.Senior VP & GM of BayMedicaMore ExecutivesKey CompetitorsKinetaNASDAQ:KAObsEvaNASDAQ:OBSVAlterity TherapeuticsNASDAQ:ATHEChromocell TherapeuticsNYSE:CHROShuttle PharmaceuticalsNASDAQ:SHPHView All CompetitorsInsidersAndrew HullBought 37,500 shares on 2/21/2024Total: $14,625.00 ($0.39/share)Eric A AdamsBought 41,600 shares on 2/20/2024Total: $14,976.00 ($0.36/share)View All Insider Transactions INM Stock Analysis - Frequently Asked Questions How have INM shares performed this year? InMed Pharmaceuticals' stock was trading at $0.4160 at the beginning of the year. Since then, INM stock has decreased by 30.6% and is now trading at $0.2885. View the best growth stocks for 2024 here. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. The firm had revenue of $1.17 million for the quarter. InMed Pharmaceuticals had a negative trailing twelve-month return on equity of 53.42% and a negative net margin of 108.02%. When did InMed Pharmaceuticals' stock split? Shares of InMed Pharmaceuticals reverse split before market open on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
